A phase 2a, double-blind, randomised, placebo-controlled trial of the myeloperoxidase inhibitor, mitiperstat, in participants with COPD
European Respiratory Journal · 2026-11 · 68 (5) · 2502567
DOI: 10.1183/13993003.02567-2025 ↗Abstract
Background Neutrophilic inflammation is a common feature of COPD. Mitiperstat, an inhibitor of myeloperoxidase expressed in neutrophils, may have potential as a COPD treatment. Methods This phase 2a, randomised, placebo-controlled, double-blind, parallel-arm, event-driven trial evaluated the efficacy and safety of mitiperstat 5 mg once daily for up to 24 weeks (CRESCENDO; ClinicalTrials.gov : NCT05492877 ). Adults (40–80 years) with moderate-to-severe COPD, at high risk of exacerbation and receiving dual or triple inhaled therapy were included. The primary end-point was time to first composite end-point for exacerbations in COPD (COPDCompEx) event. Secondary end-points included time to first moderate-to-severe COPD exacerbation, post-bronchodilator forced expiratory volume in 1 s (post-BD FEV 1 ) change at week 12, respiratory symptoms, disease impact and safety. Results Overall, 381 participants (mean age 66.0 years; 39.6% female) were randomised to mitiperstat (n=189) or placebo (n=192). In total, 125 (66.1%) mitiperstat-treated versus 125 (65.1%) placebo-treated participants experienced COPDCompEx events over 24 weeks. There was no improvement in time to first COPDCompEx event (hazard ratio (HR) 1.07, 90% CI 0.87–1.32; p=0.599) or time to first moderate-to-severe COPD exacerbation (HR 1.23, 90% CI 0.88–1.73) with mitiperstat versus placebo. Improvements in post-BD FEV 1 , respiratory symptoms or disease impact were not seen with mitiperstat. A similar proportion of participants in both groups reported adverse events; seven mitiperstat-treated participants and two placebo-treated participants had pneumonia during the study. Conclusion These results indicate that the risks outweigh the benefits of mitiperstat as a treatment for COPD.
EUVIMED